Showing 621-630 of 2293 results for "".
- Applying the 2024 McDonald Diagnostic Criteria Effective for Identifying Prodromal MS in Real-World Studyhttps://practicalneurology.com/news/applying-the-2024-mcdonald-diagnostic-criteria-effective-for-identifying-prodromal-ms-in-real-world-study/2473799/Applying the 2024 McDonald diagnostic criteria for multiple sclerosis (MS) was effective in identifying individuals with prodromal MS, according to data presented at the Americas Committee for T
- First Guidelines for De-escalating and Discontinuing MS Therapies Releasedhttps://practicalneurology.com/news/first-guidelines-for-de-escalating-and-discontinuing-ms-therapies-released/2475069/A panel of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) has developed the first comprehensive guidelines for de-escalating and discontinuing disease-modifying therapies (DMTs) in individuals diagnosed with multiple sclerosis (MS). The guidelines, published in
- Researchers Find Association Between Dysregulation of Three Genes and MShttps://practicalneurology.com/news/researchers-find-association-between-dysregulation-of-three-genes-and-ms/2470082/New research published in the Annals of Clinical and Translational Neurology has identified dysregulation in three specific genes along with their expressed proteins that may be associated with multiple sclerosis (MS). The three genes were SHMT1, FAM120B, and ICA1L. As part of
- Investigational MS Treatment Diroximel Fumarate Has Improved Gastrointestinal Tolerabilityhttps://practicalneurology.com/news/investigational-ms-treatment-diroximel-fumarate-has-improved-gastrointestinal-tolerability/2468982/Topline results from the EVOLVE-MS-2 study (NCT02634307), of diroximel fumarate (ALKS8700, BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) have been announced. Pa
- Diroximel Fumarate Treatment of Relapsing MS Has Improved Gastrointestinal Tolerability and Improved Quality of Lifehttps://practicalneurology.com/news/diroximel-fumarate-treatment-of-relapsing-ms-has-improved-gastrointestinal-tolerability-and-improved-quality-of-life/2469379/In EVOLVE-MS-2 (NCT03093324) trial of diroximel fumarate (Vumerity; Biogen, Cambridge, MA), recently approved for the treatment of relapsing forms of multiple sclerosis (MS), had significantly more gastrointestinal (GI) tolerability th
- Wearable Bladder Monitoring Device May Help Predict UTIs in Women With MShttps://practicalneurology.com/news/wearable-bladder-monitoring-device-may-help-predict-utis-in-women-with-ms/2474951/At the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers (CMSC), researchers presented promising data on the use of wearable ultrasound (US) technology to monitor urinary retention in women with multiple sclerosis (MS). The study evaluated the use of the DFree device (Dfree; Sa
- Parafoveal OCT Scans Show Promise as Biomarker of MS Progressionhttps://practicalneurology.com/news/parafoveal-oct-scans-show-promise-in-assessing-ms-progression/2473798/Anatomical variations of parafoveal retinal layer thickness measured using optical coherence tomography (OCT) were associated with clinical outcomes in individuals with multiple sclerosis (MS) according to study results presented at the Americas Committee for Treatment and Research in Multiple Sc
- Enhanced EDSS Instrument Helpful in Assessing Disability Progression in People with MShttps://practicalneurology.com/news/researchers-develop-modified-edss-tool-for-improved-measurement-of-pira-in-ms/2473795/In a recent study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, a novel assessment tool for measuring multiple sclerosis (MS) disease progression showed utility for redefining and quantifying progression independent of relapse acti
- New Study Examines the Risk of Relapse in Those Discontinuing MS Therapyhttps://practicalneurology.com/news/new-study-examines-the-risk-of-relapse-in-those-discontinuing-ms-therapy/2470432/The discontinuation of high-efficacy therapies (HETs) that impact immune cell trafficking, including Tysabri (natalizumab; Biogen, Cambridge, MA) and Gilenya (fingolimod; Novartis, East Hanover, NJ), in people aged ≥50 years with nonactive multiple sclerosis (MS) was associated with a signific
- OTC Antihistamine Clemastine May Accelerate Disability in Those with Progressive MShttps://practicalneurology.com/news/otc-antihistamine-clemastine-may-accelerate-disability-in-those-with-progressive-ms/2470414/Cutting-edge research has unveiled concerning findings regarding the use of clemastine fumarate in those with progressive multiple sclerosis (MS). The study, conducted by a team of researchers from the National Institutes of Health (NIH) and other institutions, revealed that clemastine fumar